Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 15/20 | 0.56 |
| ▸ | SCTR | P47872 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29394888 | 0.95 | GLP1R (0.58) | GLP1RSCTR | |
| SCHEMBL29860251 | 0.94 | OPRM1 (0.61) | GLP1RSCTROPRM1OPRD1OPRK1 | |
| SCHEMBL29860168 | 0.93 | OPRM1 (0.57) | GLP1RSCTROPRM1OPRD1OPRK1 | |
| SCHEMBL2468098 | 0.92 | GLP1R (0.50) | GLP1RSCTROPRM1OPRD1OPRK1 | |
| SCHEMBL31243563 | 0.92 | GLP1R (0.60) | GLP1R | |
| SCHEMBL31740815 | 0.91 | GLP1R (0.56) | GLP1RSCTR | |
| SCHEMBL30974128 | 0.91 | GLP1R (0.57) | GLP1RSCTROPRM1OPRD1 | |
| SCHEMBL29462131 | 0.90 | GLP1R (0.64) | GLP1RSCTR | |
| SCHEMBL30184796 | 0.90 | GLP1R (0.64) | GLP1RSCTR | |
| SCHEMBL30637757 | 0.90 | GLP1R (0.53) | GLP1RSCTROPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383605-B2 | Exenatide analog and use thereof | ANYGEN CO., LTD. (KR) | 2025-08-12 | — | — | US | disclosed |
| CN-115380043-A | Exenatide analogue and application thereof | 安医健有限公司 | 2022-11-22 | — | — | CN | disclosed |
| US-20220323548-A1 | EXENATIDE ANALOG AND USE THEREOF | ANYGEN CO., LTD., (KR) | 2022-10-13 | — | — | US | disclosed |
| US-11324833-B2 | Cholix-derived carriers for oral delivery of heterologous payload | APPLIED MOLECULAR TRANSPORT INC. (US) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383605-B2 | Exenatide analog and use thereof | GLP1R, IAPP, GIPR | GLP1R 1/4885SCTR 9/4885OPRM1 2354/4885 |
| US-20220323548-A1 | EXENATIDE ANALOG AND USE THEREOF | GLP1R, IAPP, GIPR | GLP1R 1/4885SCTR 9/4885OPRM1 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.